Breathe Well Live Well
|
Asthma Patients with Anxiety See More Severe Symptoms
Pharmacy Times “Anxiety sensitivity amplifies your reaction to anxiety symptoms, which are very similar to asthma symptoms,” study author Alison C. McLeish, PhD, told Pharmacy Times. “We found that people with asthma and high anxiety symptoms were more reactive to … |
View full post on asthma – Google News
|
First-in-class biologic maintenance therapy approved for severe asthma
ModernMedicine Nucala, developed by GlaxoSmithKline, is an interleukin-5 (IL-5) antagonist monoclonal antibody that reduces the production and survival of esosinophils, which are one of the inflammatory cell types involved in asthma. The biologic is to be … |
View full post on asthma – Google News
MD Magazine |
Reslizumab Positively Impacts the Quality of Life in Severe Asthma
MD Magazine Previous phase III trials have shown that reslizumab, an investigational IgG4/k humanized monoclonal antibody, improved lung function and reduced asthma exacerbations. Now Joshua Jacobs, MD, from Allergy and Asthma Clinical Research in Walnut … |
View full post on asthma – Google News
Ledger Gazette |
FDA approves Mepolizumab for maintenance treatment of severe asthma
Ledger Gazette The US Food and Drug Administration has cleared use of Nucala (mepolizumab) in patients with severe asthma aged 12 years and older whose condition is driven by eosinophilic inflammation, offering patients access to the first and only approved biologic … Nucala approved to treat severe asthma |
View full post on asthma – Google News
KRQE News 13 |
Glaxo wins US approval for drug to treat severe asthma
KRQE News 13 WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved an injectable drug from GlaxoSmithKline PLC to treat severe asthma attacks. The agency cleared Nucala for patients 12 years and older who cannot control their asthma with … |
View full post on asthma – Google News
|
Nucala approved to treat severe asthma
Examiner.com The FDA has approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older with a history severe attacks (exacerbations) despite receiving their current asthma medicines. |
View full post on asthma – Google News
|
Drug Combats Severe Asthma
Newsmax "This approval offers patients with severe asthma an additional therapy when current treatments cannot maintain adequate control of their asthma," Dr. Badrul Chowdhury, director of the FDA's pulmonary, allergy and rheumatology products division, said … |
View full post on asthma – Google News
|
FDA approves Nucala to treat severe asthma
FDA.gov The U.S. Food and Drug Administration today approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older. Nucala is approved for patients who have a history of severe … FDA Approves New Asthma Medication |
View full post on asthma – Google News
|
Joliet hospital offers new procedure to help control severe asthma
The Herald-News But now, Durham's pulmonologist Dr. Phillip Leung is recommending she undergo a new procedure designed to greatly reduce asthma in those who have severe cases. Durham is on the waiting list to receive it and is just waiting for insurance issues to … |
View full post on asthma – Google News
| Related Articles |
ERJ November Podcast: results from the adult and paediatric cohorts of the U-BIOPRED study of severe asthma.
Eur Respir J. 2015 Nov;46(5):E59
Authors:
PMID: 26521291 [PubMed – in process]
View full post on pubmed: asthma